Based upon these promising results, a phase 3 trial of IMO-2125 in combination with ipilimumab in anti-PD-1 refractory melanoma has been conducted (NCT03445533), but the preliminary results did not meet its primary ORR endpoint [124]. This evidence concerns the gene PDCD1 and melanoma.